Thus, escape from the inhibitory signaling activity of TGF-β as seen in other cancers, e.g., colon cancer, is not required in glioblastoma, at least not at the level of Smad2 canonical signaling. This evidence concerns the gene TGFB1 and malignant colon neoplasm.